Prognostic indicators for tumor recurrence after liver transplantation in hepatocellular carcinoma and related molecular targeted therapy

Oncology

Volumn 81, Issue SUPPL. 1, 2011, Pages 116-122

  Yu, Lei ^a   Dai, Zhi ^a   Wang, Zheng ^a   Fan, Jia ^a   Zhou, Jian ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Molecular targeted therapy; Prognosis; Recurrence metastasis

Indexed keywords

ANTIVIRUS AGENT; BEVACIZUMAB; CADHERIN; CATENIN; CETUXIMAB; CYTOKERATIN; DASATINIB; ERLOTINIB; GEFITINIB; GELATINASE A; GELATINASE B; GEMCITABINE; IMATINIB; LEPTIN; LICARTIN; LY 2109761; MATRIX METALLOPROTEINASE 14; MOLECULAR THERAPY AGENT; OSTEOPONTIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; PROTEIN P53; SORAFENIB; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CELL GROWTH; COLON CANCER; DRUG EFFICACY; EXTRACELLULAR MATRIX; FIBROSARCOMA; GENE MUTATION; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE INFECTION; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REGULATORY MECHANISM; REVIEW; SURVIVAL RATE; TREATMENT INDICATION; TUMOR SUPPRESSOR GENE; VIRUS ONCOGENE;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84855328731     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333273     Document Type: Review

References (30)

1. Guzman G, Alagiozian-Angelova V, Layden-Almer JE, Layden TJ, Testa G, Benedetti E, Kajdacsy-Balla A, Cotler SJ: p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Mod Pathol 2005;18:1498-1503. (Pubitemid 41509405)
2. Marsh JW, Finkelstein SD, Demetris AJ, Swalsky PA, Sasatomi E, Bandos A, Subotin M, Dvorchik I: Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl 2003;9:664-671. (Pubitemid 36874451)
3. Ramos E, Lladó L, Serrano T, Figueras A, Lastra R, Torras J, Figueras J, Rafecas A, Fabregat J: Utility of cell-cycle modulators to predict vascular invasion and recurrence after surgical treatment of hepatocellular carcinoma. Transplantation 2006;82:753-758. (Pubitemid 44470377)
4. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS: Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007;117:2713-2722. (Pubitemid 47494371)
5. Fiorentino M, Altimari A, Ravaioli M, Gruppioni E, Gabusi E, Corti B, Vivarelli M, Bringuier PP, Scoazec JY, Grigioni WF, D'Errico-Grigioni A: Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation. Clin Cancer Res 2004;10:1789-1795. (Pubitemid 38435570)
6. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC: High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 2004;112:44-50. (Pubitemid 39249490)
7. Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS: Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 2008;8:212-226. (Pubitemid 351301854)
8. Sieghart W, Wang X, Schmid K, Pinter M, König F, Bodingbauer M, Wrba F, Rasoul-Rockenschaub S, Peck-Radosavljevic M: Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol 2011;54:89-97.
9. Nart D, Yaman B, Yilmaz F, Zeytunlu M, Karasu Z, Kiliç M: Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation. Liver Transpl 2010;16:621-630.
10. Wu LM, Zhang F, Xie HY, Xu X, Chen QX, Yin SY, Liu XC, Zhou L, Xu XB, Sun YL, Zheng SS: MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation. Clin Genet 2008;73:273-278. (Pubitemid 351228515)
11. Ben-Ari Z, Pappo O, Druzd T, Sulkes J, Klein T, Samra Z, Gadba R, Tambur AR, Tur-Kaspa R, Mor E: Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine 2004;27:7-14. (Pubitemid 38780932)
12. Man K, Lo CM, Xiao JW, Ng KT, Sun BS, Ng IO, Cheng Q, Sun CK, Fan ST: The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg 2008;247:1049-1057. (Pubitemid 351770427)
13. Oya H, Sato Y, Yamamoto S, Nakatsuka H, Kobayashi T, Hara Y, Waguri N, Suda T, Aoyagi Y, Hatakeyama K: Comparison between human-telomerase reverse transcriptase mRNA and alpha-fetoprotein mRNA as a predictive value for recurrence of hepatocellular carcinoma in living donor liver transplantation. Transplant Proc 2006;38:3636-3639. (Pubitemid 44908547)
14. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V, Roskams T: The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma: a possible progenitor cell origin. Histopathology 2006;49:138-151. (Pubitemid 44079697)
15. Cheung ST, Fan ST, Lee YT, Chow JP, Ng IO, Fong DY, Lo CM: Albumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinoma. Transplantation 2008;85:81-87.
16. Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F, Zheng SS: Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011;18:1243-1250.
17. Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, Harada N, Yamashita Y, Sugimachi K, Kayashima H, Iguchi T, Maehara Y: Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009;87:531-537.
18. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Kaiser GM, Schmid KW, Baba HA: Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis. J Clin Pathol 2009;62:690-693.
19. Wu LM, Yang Z, Zhou L, Zhang F, Xie HY, Feng XW, Wu J, Zheng SS: Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One 2010;5:e14460.
20. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, Lemoine A, Bismuth H, Castaing D, Adam R: Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010;10:129-137.
21. Mailey B, Artinyan A, Khalili J, Denitz J, Sanchez-Luege N, Sun CL, Bhatia S, Nissen N, Colquhoun SD, Kim J: Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg 2011;146:26-33.
22. Sun H, Teng M, Liu J, Jin D, Wu J, Yan D, Fan J, Qin X, Tang H, Peng Z: FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria. Cancer Lett 2011;306:214-222.
23. Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C, Samuel D: Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008;134:1890-1899. (Pubitemid 351783254)
24. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW, Baba HA: Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008;48:83-90. (Pubitemid 350191996)
25. Chen ZN, Mi L, Xu J, Song F, Zhang Q, Zhang Z, Xing JL, Bian HJ, Jiang JL, Wang XH, Shang P, Qian AR, Zhang SH, Li L, Li Y, Feng Q, Yu XL, Feng Y, Yang XM, Tian R, Wu ZB, Leng N, Mo TS, Kuang AR, Tan TZ, Li YC, Liang DR, Lu WS, Miao J, Xu GH, Zhang ZH, Nan KJ, Han J, Liu QG, Zhang HX, Zhu P: Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 2006;65:435-444.
26. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, Xu HY, Song F, Yang XM, Mi L, Zhao QC, Tian R, Feng Q, Zhang SH, Li Y, Jiang JL, Li L, Yu XL, Zhang Z, Chen ZN: A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007;45:269-276. (Pubitemid 46374583)
27. Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi SS, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M, Taieb J: Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008;112:2733-2739. (Pubitemid 351969218)
28. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD: Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992-2998.
29. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, Chang SS, Chen PJ: Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009;50:958-968.
30. Yeganeh M, Finn RS, Saab S: Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant 2009;9:2851-2854.